CIK 1917529
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 100.00% | 6 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | KYMR | Kymera Therapeutics, Inc. | Health Care | 48.26% |
| 2 | DYN | Dyne Therapeutics, Inc. | Health Care | 20.95% |
| 3 | SION | Sionna Therapeutics, Inc. | Health Care | 15.20% |
| 4 | IRON | Disc Medicine, Inc. | Health Care | 12.25% |
| 5 | QTTB | Q32 Bio Inc. | Health Care | 1.70% |
| 6 | KRRO | Korro Bio, Inc. | Health Care | 1.63% |
6/6 names classified · sector 100.0% of weight · industry 100.0% · mkt cap 100.0%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 100.0% of the book is sector-classified (unclassified names shown, never dropped).
Only 2% of book weight classified — the grid is NOT representative of the whole book.
Classified: 1.7% of book weight (1/6 names) · unclassified 98.3%: KYMR, DYN, SION, IRON, KRRO. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | KYMRKYMERA THERAPEUTICS INC | 4,578,008 | $381M | 48.3% | HOLD |
| 2 | DYNDYNE THERAPEUTICS INC | 9,130,465 | $166M | 21.0% | HOLD |
| 3 | SIONSIONNA THERAPEUTICS INC | 2,995,602 | $120M | 15.2% | HOLD |
| 4 | IRONDISC MEDICINE INC | 1,513,875 | $97M | 12.3% | HOLD |
| 5 | QTTBQ32 BIO INC | 2,092,106 | $13M | 1.7% | HOLD |
| 6 | KRROKORRO BIO INC | 1,137,149 | $13M | 1.6% | HOLD |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| KYMRKYMERA THERAPEUTICS INC | 4.9M | 4.9M | 4.9M | 4.9M | 4.7M | 4.6M | $381M |
| DYNDYNE THERAPEUTICS INC | 8.0M | 9.1M | 9.1M | 9.1M | 9.1M | 9.1M | $166M |
| SIONSIONNA THERAPEUTICS INC | — | 3.7M | 3.7M | 3.6M | 3.0M | 3.0M | $120M |
| IRONDISC MEDICINE INC | 2.5M | 2.4M | 2.4M | 2.1M | 1.5M | 1.5M | $97M |
| QTTBQ32 BIO INC | 2.1M | 2.1M | 2.1M | 2.1M | 2.1M | 2.1M | $13M |
| KRROKORRO BIO INC | 1.1M | 1.1M | 1.1M | 1.1M | 1.1M | 1.1M | $13M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
